Is meloxicam a non‑steroidal anti‑inflammatory drug (NSAID) and what are its indications, recommended dosing, contraindications, and alternative options?

Meloxicam Classification and Clinical Profile

Yes, meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2) over COX-1, providing anti-inflammatory, analgesic, and antipyretic effects with a favorable gastrointestinal safety profile compared to traditional NSAIDs. 1, 2, 3

Drug Classification and Mechanism

• Meloxicam is classified as a preferentially selective COX-2 inhibitor NSAID, distinguishing it from non-selective NSAIDs and highly selective COX-2 inhibitors like celecoxib 2, 3, 4
• It inhibits the inducible COX-2 enzyme (mediating inflammation, pain, and fever) more than the constitutive COX-1 enzyme (responsible for gastric protection, renal perfusion, and platelet function) 2, 3, 4
• The pharmacokinetic profile includes >99% protein binding, 20-hour elimination half-life enabling once-daily dosing, and metabolism to four inactive metabolites 4, 5

Approved Indications

• Osteoarthritis: Meloxicam 7.5-15 mg daily demonstrates efficacy comparable to naproxen 750-1000 mg, piroxicam 20 mg, and diclofenac 100 mg 2, 3
• Rheumatoid arthritis: Meloxicam 15 mg daily maintains sustained efficacy over 18 months with 66% of patients continuing therapy 6
• Preemptive analgesia: Meloxicam is recommended as first-line preemptive NSAID for postoperative hysterectomy pain, reducing both pain scores and total narcotic consumption 1

Recommended Dosing

• Standard dosing: 7.5 mg once daily (lower dose) or 15 mg once daily (higher dose) 1, 2
• Steady-state plasma concentrations achieved within 3-5 days of daily administration 5
• Once-daily dosing is appropriate due to the 20-hour half-life 4, 5
• The 7.5 mg dose provides effective analgesia with the lowest gastrointestinal risk profile 2

Contraindications and High-Risk Situations

• Absolute avoidance: Patients with history of NSAID-associated upper GI bleeding should avoid meloxicam unless combined with proton pump inhibitor (PPI) or misoprostol 1
• Cardiovascular risk: Regular long-term meloxicam use increases risk of intracerebral hemorrhage and should be avoided in patients with prior ICH 1
• Renal impairment: Use with extreme caution in patients with preexisting renal disease, congestive heart failure, or cirrhosis due to risk of acute renal failure 1
• Anticoagulation: Avoid combining with warfarin or other anticoagulants as this increases GI bleeding risk 3-6 fold and raises INR by up to 15% 1
• Cardiovascular disease: Meloxicam demonstrates increased cardiovascular risk similar to other NSAIDs, particularly in patients with established cardiovascular disease 1

Gastrointestinal Safety Profile

• Meloxicam produces significantly fewer GI adverse effects than traditional NSAIDs: perforations, ulcerations, and bleeding occurred in only 0.1% (7.5 mg) and 0.2% (15 mg) of patients compared to 1.2% with piroxicam and 2.1% with naproxen 2
• Severe GI effects occurred in only 0.8% of patients during 18-month trials, with only 3.9% discontinuing due to GI adverse events 6
• The improved safety profile results from preferential COX-2 selectivity, causing less gastric mucosal damage than piroxicam on endoscopy 3
• Risk mitigation: For patients requiring meloxicam with GI risk factors (age >60, history of peptic ulcer, concurrent steroids), combine with PPI or H2-blocker 1

Alternative Options When Meloxicam is Inappropriate

For acute pain without significant inflammation:

• Ibuprofen is preferred as first-line NSAID due to high analgesic effect at low doses (400-800 mg three times daily) with minimal anti-inflammatory activity, making it less ulcerogenic 7
• Cost-effective: generic ibuprofen costs $16-28 monthly versus meloxicam $13-32 monthly 1

For chronic inflammatory conditions:

• Naproxen 250-500 mg twice daily is preferred for rheumatoid arthritis and juvenile idiopathic arthritis due to established long-term safety and twice-daily convenience 7, 8
• Indomethacin 50 mg three times daily is preferred for acute inflammatory arthritis like gout 7

When all NSAIDs are contraindicated:

• Acetaminophen 650 mg every 4-6 hours (maximum 4g/day) as first-line alternative, though with less anti-inflammatory effect 9
• Non-acetylated salicylates (salsalate 750 mg twice daily) if additional anti-inflammatory effect needed, as these do not inhibit platelet aggregation 9
• Celecoxib (selective COX-2 inhibitor) 100-200 mg twice daily may be considered for GI risk but NOT cardiovascular risk, as it increases cardiovascular events 1, 9

Critical Clinical Pitfalls

• Do not assume GI symptoms predict ulceration: Dyspepsia occurs in 10-20% of NSAID users but does not correlate with clinically significant ulcerations 1
• Monitor blood pressure: All NSAIDs including meloxicam can increase mean blood pressure by 5 mm Hg and worsen hypertension 1
• Avoid in late pregnancy: NSAIDs should be discontinued 6-8 weeks before delivery to prevent premature ductus arteriosus closure and prolonged gestation 8
• Bleeding risk persists: Even with COX-2 preferential agents like meloxicam, the 5% six-month recurrent bleeding risk in patients with prior GI bleeding remains significant 1